Advanced in Peripheral T-Cell Lymphoma

Dr. Martha J. Glenn

Oncology | Hematology
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
Advanced in Peripheral T-Cell Lymphoma
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Martha Glenn is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Glenn is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 52 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in UT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: TAA-T cells, Nivolumab
Study Phase: Phase 1
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
View 3 Less Clinical Trials

52 Total Publications

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Journal: Blood advances
Published: May 22, 2024
Similar Doctors
Advanced in Peripheral T-Cell Lymphoma
Dr. Gabriela Motyckova
Hematology Oncology | Hematology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Gabriela Motyckova
Hematology Oncology | Hematology | Oncology

Ihc Health Services Inc

8 Th Ave C St, 
Salt Lake City, UT 
 (2.3 miles away)
801-408-1146
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gabriela Motyckova is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Motyckova is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Motyckova is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. Bryan D. Huber
Hematology Oncology | Hematology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Bryan D. Huber
Hematology Oncology | Hematology | Oncology

Ihc Health Services Inc

8 Th Ave C St, 
Salt Lake City, UT 
 (2.3 miles away)
801-408-1146
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bryan Huber is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Huber is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. Finn B. Petersen
Hematology Oncology | Hematology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Finn B. Petersen
Hematology Oncology | Hematology | Oncology
E8 Lds Hospital, 8th Avenue And C Street, 
Salt Lake City, UT 
 (3.0 miles away)
801-408-1819
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Finn Petersen is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Petersen is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Petersen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glenn's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile